Posted by Michael Wonder on 04 Mar 2020
PHARMAC confirms new breast cancer medicine to be funded
4 March 2020 - New Zealanders with advanced breast cancer will be able to access palbociclib (marketed as Ibrance) from 1 April this year, which could stop or slow down the progression of their cancer.
“The feedback we received on palbociclib during the consultation phase was overwhelmingly positive,” says PHARMAC’s Chief Executive Sarah Fitt.
“We are delighted that we have been able to come to an agreement with the supplier Pfizer to fund both first line and second or subsequent lines of treatment.”
